Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2006-11-20
2011-10-11
Wehbe, Anne Marie S (Department: 1633)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C435S325000, C435S001100, C800S017000, C800S021000
Reexamination Certificate
active
08034330
ABSTRACT:
It has been discovered that there are at least two significant antigens present on the cells of animal species such as pigs that elicit an immune or inflammatory response immediately upon implantation into humans or contact with human serum. The first is an α-galactosyl (Gal) epitope, for example, Galα(1→3)Galβ(1→4)GlcNac (linear B type 2) or Galα (1→3)Galβ(1→4)Glc (linear B type 6). The second is an N-glycolylneuraminic acid (NeuGc) structure. By eliminating these epitopes, preferably by genetically engineering the animal so that the epitope is either not produced or is greatly reduced, or by chemical or enzymatic treatment of the animal's cells to remove the epitopes, it is possible to produce organs, tissues and cells suitable for xenotransplantation into humans. Cells can be rendered even more compatible by genetically engineering the animal to express a human complement regulatory protein (inhibitor), such as CD59, on its cells, or to express an excess of a pig complement regulatory protein.
REFERENCES:
patent: 6166288 (2000-12-01), Diamond et al.
patent: 6228631 (2001-05-01), Zhu et al.
patent: 6245890 (2001-06-01), Zhu et al.
patent: 6331658 (2001-12-01), Cooper et al.
patent: 0 517 916 (1992-12-01), None
patent: WO 92/17189 (1992-10-01), None
patent: WO 95/20661 (1995-08-01), None
patent: WO 97/12035 (1997-04-01), None
Bouhours et al. (1996) Glycoconj. J., vol. 13, 947-953.
Fontana et al. (1999) Animal Cell Technology: Products from Cells, Cells as Products-Proceedings of the 16th ESACT Meeting, Apr. 25-29, 1999, Lugano, Switzerland, 245-247, and 249.
Irie, et al., “The molecular basis for the absence of N-glycolylneuraminic acid in humans”, J. Biol. Chem., 273(25):15866-15871 (1998).
Okajima, “Molecular cloning of a novel alpha2,3-sialyltransferase (ST3Gal VI) that sialylates type II lactosamine structures on glycoproteins and glycolipids”, J. Biol. Chem., 274(17):11479-11486 (1999).
Hamanaka, et al., “Occurrence of hematoside with two moles of N-acetyl-neuraminic acid in a certain breed of Persian cat”,J. Biochem., 86:695-698 (1979).
Hashimoto, et al., “Further studies on the red cell glycolipids of various breeds of dogs. A possible assumption about the origin of Japanese dogs”,J. Biochem., 96:1777-1782 (1984).
Alwayn, et al., “The problem of anti-pig antibodies in pig-to-primate xenografting: current and novel methods of depletion and/or suppression of production of anti-pig antibodies,”Xenotransplantation. 6(3):157-168 (1999).
Asaoka, et al., “Detection of N-glycolylneuraminic acid-containing glycoproteins from various animal erythrocytes by chicken monoclonal antibody against Hanganutziu-Deicher antigens,”J Vet Med Sci56(2):375-377 (1994).
Backer, et al., “Biochemical and enzymatic characterization of blood group ABH and related histo-blood group glycosphingolipids in the epithelial cells of porcine small intestine,”Glycobiology7(7): 943-953 (1997).
Bouhours, et al., “A novel glycosphingolipid expressed in pig kidney: Gal alpha 1-3Lewis(x) hexaglycosylceramide,”Glycoconj. J.14(1): 29-38 (1997).
Bouhours, et al., “Simultaneous expression by porcine aorta endothelial cells of glycosphingolipids bearing the major epitope for human xenoreactive antibodies (Gal alpha 1-3Gal), blood group H determinant and N-glycolylneuraminic acid,”Glycoconj J13(6): 947-953 (1996).
Brinkman-Van Der Linden, et al., “Loss of N-glycolyIneuraminic acid in human evolution. Implications for sialic acid recognition by siglecs,”J. Biol.Chem.275(12): 8633-8640 (2000).
Buhler, et al., “High-dose porcine hematopoietic cell transplantation combined with CD40 ligand blockade in baboons prevents an induced anti-pig humoral response,”Transplantation69(11) 2296-2304 (2000).
Buhler, et al., “Miniature swine and hDAF pig kidney transplantation in baboons treated with a nonmyeloablative regimen and CD154 blockade,”Transplant. Proc.33(1-2):716 (2001).
Buhler, et al., “Xenotransplantation—state of the art—update 1999,”Front Biosci4: d416-432 (1999).
Cairns, et al., “Thomsen-Friedenreich and PK antigens in pig-to-human xenotransplantation,”Transplant. Proc.28(2):795-796 (1996).
Chou, et al., “A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence,”Proc. Natl. Acad. Sci. U S A.95(20):11751-11756 (1998).
Colman, et al., “Therapeutic cloning: concepts and practicalities,”Trends Biotechnol18(5):192-196 (2000).
Cooper, “Depletion of natural antibodies in non-human primates—a step towards successful discordant xenografting in humans,”Clin. Transplant6(3 Pt 1):178-183 (1992).
Cooper, “Xenoantigens and xenoantibodies,”Xenotransplantation5(1):6-17 (1998).
Cooper, et al., “Manipulation of the anti-alphaGal antibody—alphaGal epitope system in experimental discordant xenotransplantation,”Xenotransplantation3: 102-111 (1996).
Cooper, et al., “The pig as potential organ donor for man,”Xenotransplantation(Cooper, et al., eds.) pp. 481-500 Springer: Heidelberg, 1991.
Cooper, et al., “Extracorporeal immunoadsorption of alpha-Gal antibodies,” Xeno 4(2): 27-29 (1996).
Cooper, et al., “Effects of cyclosporine and antibody adsorption on pig cardiac xenograft survival in the baboon,”J. Heart Transplant7(3):238-246 (1988).
Cooper, et al., “Genetically engineered pigs,”Lancet342(8872):682-683 (1993).
Cooper, et al., “Identification of alpha-galactosyl and other carbohydrate epitopes that are bound by human anti-pig antibodies: relevance to discordant xenografting in man,”Transpl Immunol1{3}: 198-205 (1993).
Cooper, et al., “Oligosaccharides and discordant xenotransplantation,”Immunol. Rev.141:31.58 (1994).
Cozzi, et al., “Effect of transgenic expression of human decay-accelerating factor on the inhibition of hyperacute rejection of pig organs,”Xenotransplantation(Second edition) (Cooper et al., eds.), pp. 665-682, Springer: Berlin, 1997.
Cozzi, et al., “The generation of transgenic pigs as potential organ donors for humans,”Nature Med1(9):964-966 (1995).
Dalmasso, et al., “Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor. Potential for prevention of xenograft hyperacute rejection,”Transplantation52(3):530-533 (1991).
Dorling, et al., “Clinical xenotransplantation of solid organs,”Lancet349(9055):867-871 (1997).
Galili, “The two antibody specificities within human anti-blood group B antibodies,”Transfusion Med. Rev.2(2):112-121 (1988).
Galili, et al., “Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells,”J Biol Chem263(33): 17755-17762 (1988).
Galili, et al., “The human natural anti-Gal IgG. III. The subtlety of immune tolerance in man as demonstrated by crossreactivity between natural anti-Gal and anti-B antibodies,”J.Exp. Med.165(3):693-704 (1987).
Gentsch and Pacitti, “Effect of neuraminidase treatment of cells and effect of soluble glycoproteins on type 3 reovirus attachment to murine L cells”,J. Virol., 56(2):356-64 (1985).
Good, et al., “Identification of carbohydrate structures that bind human antiporcine antibodies: implications for discordant xenografting in humans,”Transplant. Proc.24(2):559-562 (1992).
Hansson, “Structural aspects of blood group glycosphingolipids in the gastrointestinal tract,”Adv Exp Med Biol228:465-494 (1988).
Hantzopoulos, et al., “Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector,”Proc. Natl. Acad. Sci. USA86(10):3519-3523 (1989).
Hinchliffe, et al., “Molecular cloning and functional ch
Pabst Patent Group LLP
RBC Biotechnology, Inc.
Wehbe Anne Marie S
LandOfFree
Modified organs and cells for xenotransplantation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified organs and cells for xenotransplantation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified organs and cells for xenotransplantation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4283004